Clinical Trial Update: Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib

View source ↗

Summary

A completed clinical trial evaluating metabolic outcomes in patients with chronic myeloid leukemia treated with the tyrosine kinase inhibitors dasatinib or nilo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Sprycel (dasatinib)
• Tasigna (nilotinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Chronic Myeloid Leukemia (CML) | Status: COMPLETED